Citigroup Maintains Neutral on Edwards Lifesciences, Raises Price Target to $98
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Joanne Wuensch maintains a Neutral rating on Edwards Lifesciences (NYSE:EW) and raises the price target from $90 to $98.
April 03, 2024 | 3:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Citigroup maintains a Neutral rating on Edwards Lifesciences and raises the price target from $90 to $98.
The increase in price target by Citigroup suggests a positive outlook on the stock's future performance, potentially leading to a short-term increase in stock price. However, the Neutral rating indicates that the stock might not outperform the market significantly.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100